重组人白介素-11衍生物治疗恶性肿瘤化疗后血小板减少的临床观察OA
Clinical Observation of Recombinant Human Interleukin 11 Derivative in the Treatment of Malignant Tumor ;Chemotherapy-induced Thrombocytopenia
目的：通过与重组人白细胞介素-11(吉巨芬)对比,探讨重组人白细胞介素-11衍生物(百杰依)治疗恶性肿瘤化疗后血小板减少的疗效及安全性。方法采用自身对照研究将50例化疗后PLT＜50×109/L的恶性肿瘤患者分为百杰依组和吉巨芬组。百杰依组第1疗程接受百杰依(1.5 mg)治疗,第2疗程改用吉巨芬(3 mg)治疗,吉巨芬组用药顺序与百杰依组相反。PLT升至100×109/L以上时停药。观察两组的治疗效果、外周血血小板的变化以及不良反应发生情况。结…查看全部>>
Objective To investigate the efficacy and safety of recombinant human interleukin 11 derivative (Baijieyi) in treatment of malignant tumor chemotherapy-induced thrombocytopenia (CIT) compared with rhIL-11 (Jijufen). Methods 50 cases of malignant tumor patients whose PLT<50 × 109/L were divided into Baijieyi group and Jijufen group according to self-control study. Baijieyi group was given Baijieyi (1.5 mg) after the first chemotherapy treatment, and given …查看全部>>
李玉齐;陈斯泽;舒阳春;秦鑫添;刘栋;王希成
广东药学院附属第一医院肿瘤科，广东广州510080广东药学院附属第一医院肿瘤科，广东广州510080广东药学院附属第一医院肿瘤科，广东广州510080广东药学院附属第一医院肿瘤科，广东广州510080广东药学院附属第一医院肿瘤科，广东广州510080广东药学院附属第一医院肿瘤科，广东广州510080
医药卫生
重组人白细胞介素-11恶性肿瘤化疗血小板减少症
Recombinant human interleukin-11 (rhIL-11)Chemotherapy for malignant tumorThrombocytopenia
《临床医学工程》 2015 (10)
1351-1353,3
评论